Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of APG-1387 combined with toripalimab in advanced solid tumors
CTR20200139Phase 2Terminated
- Sponsor
- Ascentage Pharma
- Start
- Apr 2020
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dasminapant in Nonhematologic neoplasms, colorectal cancer (CRC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), sponsored by Ascentage Pharma. Started Apr 2020; status: terminated.
02
Drugs
dasminapant
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)nasopharyngeal carcinoma (NPC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20200139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200139.